ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Development of atrioventricular valve regurgitation following transcatheter aortic valve replacement for severe aortic stenosis.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcomitant mitral (MR) and/or tricuspid regurgitation (TR) in patients with aortic stenosis (AS) is often regarded as a late-stage disease manifestation, resulting from left ventricular damage, pulmonary hypertension, and right heart dysfunction. However, we assume that atrioventricular valve regurgitation in the context of severe AS may often develop as an independent entity, but knowledge regarding these patients and their risk factors is scarce.
objectivesThe aim of this study was to characterize patients who develop atrioventricular valve regurgitation after transcatheter aortic valve replacement (TAVR) and its impact on mortality.
methodsWe analyzed patients with severe AS but without concomitant atrioventricular valve disease undergoing TAVR between January 2016 and December 2021. Novel MR and/or TR ≥ grade 2 and its impact on 3-year all-cause and cardiovascular mortality were evaluated.
resultsA total of 1034 TAVR patients without preexisting atrioventricular valve regurgitation were included in the study. Of these, 114 patients (11.0%) developed relevant mitral and/or tricuspid regurgitation. Among them, 17 patients experienced combined MR and TR, 75 patients had isolated MR, and 22 patients had isolated TR. The development of atrioventricular valve regurgitation after TAVR was associated with significantly increased 3-year all-cause (p < 0.01) and cardiovascular mortality (p < 0.001).
conclusionsIn patients with severe AS but without concomitant atrioventricular valve disease at baseline, a relevant proportion of patients developed MR and/or TR after TAVR despite the relief of outflow obstruction. Moreover, patients with new-onset atrioventricular valve regurgitation had a significantly higher 3-year all-cause and cardiovascular mortality.
Indexed as
Identifiers
42573757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.